ArticleBiology direct2026
Identification and functional validation of mitochondria-related genes associated with tubular injury in kidney transplantation and ischemia-reperfusion injury.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundIschemia–reperfusion injury (IRI) limits graft function and long-term outcomes after kidney transplantation. Proximal tubular (PT) cells are highly mitochondria-rich and metabolically active, making them vulnerable to ischemic and oxidative stress. However, the molecular mechanisms linking mitochondrial dysfunction to graft function remain incompletely understood.
methodsWe integrated single-nucleus RNA sequencing, bioinformatics analyses, and experimental validation to identify mitochondria-associated genes in PT cells related to graft injury and vulnerability in the transplant setting. Mitochondria-related differentially expressed genes (Mito-DEGs) were used to construct machine learning models for delayed graft function (DGF) risk stratification. The candidate gene HAO2 was further evaluated by immunohistochemistry (IHC) in kidney transplant biopsies, a murine IRI model, and H₂O₂-treated HK-2 cells. Human biopsy samples were obtained at or prior to reperfusion and may not fully capture the extent of post-transplant IRI. Both overexpression and siRNA-mediated knockdown were performed to assess its function. Cell viability, apoptosis, and mitochondrial function were assessed using standard assays.
resultsPT cells from acute kidney injury samples exhibited mitochondrial dysfunction and metabolic impairment. Donor kidney clustering suggested heterogeneity in DGF risk associated with mitochondrial bioenergetic capacity. An eight-gene Mito-DEG signature demonstrated moderate performance in stratifying DGF risk. IHC analysis demonstrated that HAO2 expression was reduced in DGF recipient biopsies. Consistently, HAO2 was downregulated in murine IRI kidneys and injured HK-2 cells. Functionally, HAO2 overexpression alleviated oxidative stress, apoptosis, and mitochondrial dysfunction, whereas HAO2 knockdown exerted opposite effects and further aggravated H₂O₂-induced injury. Regulatory analysis identified 14 miRNAs and four TFs potentially controlling HAO2, while downstream pathways linked HAO2 to amino acid and fatty acid metabolism, extracellular matrix organization, and immune responses.
conclusionsThese findings suggest that HAO2 may serve as a functional indicator of mitochondrial metabolic capacity associated with graft vulnerability rather than being specific to IRI alone. Given the observational nature of the clinical data, further studies are required to determine whether HAO2 provides added value beyond established histopathological assessment and to clarify its potential role in guiding mitochondrial-targeted conditioning strategies, such as oxygenated machine perfusion, aimed at preserving graft function during transplantation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.